A monoclonal antibody produced by recombinant DNA technology used in the prevention of respiratory syncytial virus (RSV) infections.
A humanized monoclonal antibody (IgG) directed against an epitope in the A antigenic site of the F protein of RSV.
The agents targets the fusion protein of RSV and inhibits entry into the cell and thereby preventing infection.
Recommended for infants that are high-risk because of prematurity or other medical problems such as congenital heart disease.
Reduces the risk of hospitalization due to RSV infection by 45%-55%.
Given once a month intramuscularly, during the RSV season.
The American Academy of Pediatrics recommendations for the use of palivizumab: is used only for prevention, not for treatment, and once initiated for a given RSV season.
Prophylaxis use includes: Prematurity ≤ 28 weeks gestation and < 12 months of age at the start of RSV season
29-32 weeks gestation and < 6 months of age at the start of RSV season
32-35 weeks gestation and < 3 months of age at the start of RSV season, if there is a risk factor present.
Chronic lung disease of prematurity
Congenital heart disease
Cyanotic heart disease, for the first 24 months of life
Moderate to severe pulmonary hypertension, for the first 24 months of life
Congestive heart failure requiring medication, for the first 24 months of life
Children who have undergone open heart surgery during RSV season
Immunosuppressed individuals
Cystic fibrosis